BUSINESS

Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout

January 31, 2024

Teva Takeda Pharma and Teva Takeda Yakuhin said on January 30 that they are restricting their shipments of eight products as the New Year’s earthquake caused delays in the deliveries of some products from a contract manufacturer.

The companies decided on the move to ensure stable drug supplies amid the delivery delay from Kokando. Subject to the restrictions are one product owned by Teva Takeda Pharma as the marketing authorization holder, Candesartan Tablets 8 mg “Takeda Teva”, as well as seven products held by Teva Takeda Yakuhin - Cercine Tablets 2 mg (diazepam), Takelda Combination Tablets (lansoprazole + aspirin), Ecard Combination Tablets LD/HD (candesartan + hydrochlorothiazide), Takepron OD Tablets 15/30 (lansoprazole), and Blopress Tablets 2 (candesartan).

BUSINESS

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…